Implications of Anesthetics on Sleep Consolidation

NCT04329091 | Terminated Phase 4 Results FDA Drug

• 1 other identifier: IRB19-1442
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

Sleep leads to consolidation of learning in humans, restoring memories that were forgotten over a waking day and protecting memories against future forgetting. Although theories of consolidation have linked sleep spindles seen on electroencephalography to consolidation due to their putative role in hippocampal transfer to the neocortex (Antony et al, 2019; Antony \& Paller, 2017), spindles have not yet been linked to consolidation of perceptual learning or generalized learning. Prior research by a collaborator on this project has shown that sleep specifically aids in the consolidation of generalized perceptual learning of speech (Fenn, Nusbaum, \& Margoliash, 2003). Subjects show a 10-point reduction in performance after a waking retention period, while no loss is found after a retention period containing sleep (Fenn et al., 2003). Various measurable activities in the brain are associated with memory consolidation during sleep. This project intends study the effect of dexmedetomidine on memory consolidation during sleep Hypothesis 1 The gain in perceptual learning after a 90 minute natural sleep nap will also occur after 90 minutes of a sufficient dose of IV dexmedetomidine to replicate sleep. This result would suggest that consolidation can occur under this anesthetic state of consciousness. Hypothesis 2 The number and quality of sleep spindles seen on EEG in subjects administered dexmedetomidine will correlate with this gain in perceptual learning. This result would suggest that biomimetic sleep spindles are sufficient for producing memory consolidation. Only those subjects capable of giving their own consent will be considered for this study. The study will enroll 20 healthy subjects for this study between the ages of 18 and 35. All volunteers will be fit and healthy, meeting the American Society of Anesthesiologists (ASA) physical status classification ASA 1 (normal healthy subjects) and ASA 2 (stable chronic condition) and of normal body habitus. Prior to the study enrollment, each volunteer will sign an informed consent form. A standard anesthetic medical history will be taken in addition to performing a focused standard pre-anesthetic physical examination in order to rule out active and chronic medical problems.

Conditions

Sleep

Outcome Measures

Primary Outcomes (1)

• Perceptual Learning Protocol

  Subjects are tested in the morning for word recognition on hard-to-understand speech, then trained on this speech (never hearing the same words twice) which produces about 20 percentage points of improvement. After sedation subjects are re-tested. During the morning, afternoon and evening post-tests, subjects will be tested on new spoken words. At each time point where the perceptual learning protocol is administered the number of words correctly perceived out of 50 will be measured.

  1 day

Study Arms (1)

Dexmedetomidine Arm

EXPERIMENTAL

Dexmedetomidine: Administration of a 0.5 mcg/kg bolus followed by an infusion of 0.5-0.7 mcg/kg/hr, titrated up by 0.1 mcg every 1 minute until the subject spontaneously closes his or her eyes. When the subject spontaneously closes his or her eyes the infusion continues for 90 minutes from that point.

Drug: Dexmedetomidine

Interventions

Dexmedetomidine DRUG

All subjects will receive Dexmedetomidine to induce sedation between their pre-sedation and post-sedation perceptual learning tests.

Also known as: Precedex

Dexmedetomidine Arm

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age between 18-35
• Native English speaking
• No hearing or speech difficulties
• No psychiatric, neurologic, or sleep disorders

You may not qualify if:

• Non-smokers (within 3 months)
• Non-users of recreational or illicit drugs (including marijuana)
• Must be willing and able to pass the drug tests (no psychoactive substances), no ingestion of alcohol or sleep-altering drugs for the 48 hours prior to the study session.
• Normal weight
• Speech difficulties/disorders
• Hearing difficulties (including occluded or infected ear canals)
• Current hairstyles that do not allow the high-density EEG cap to make contact with the scalp (e.g., individuals with hair extensions, braids, dreadlocks or hairstyles that restrict the ability of electrodes to touch the scalp)
• Metal on/in/near their heads (including jewelry) that cannot be removed for the duration of the study
• Metal implants
• Serious abusers of alcohol or caffeine.
• Existing or suspected psychological or neurological disorders
• Pregnancy or suspected pregnancy (urine pregnancy test at visit 2)
• Chronic or transient (e.g., jet lag) problems with sleep; suspected sleep disorder
• Abnormal sleep habits, such as:
• Sleeping less than 5 hours each night

Sponsors & Collaborators

• University of Chicago: lead

Study Sites (1)

University of Chicago Medicine

Chicago, Illinois, 60637, United States

Location

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Al McAuley, Clinical Research Manager
• Organization: UNIVERSITY OF CHICAGO

amcauley1@bsd.uchicago.edu

7738343274

Study Officials

• Anna Clebone, MD

  University of Chicago

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2020
• First Posted: April 1, 2020
• Study Start: October 16, 2020
• Primary Completion: December 20, 2021
• Study Completion: December 20, 2021
• Last Updated: February 24, 2023
• Results First Posted: February 24, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)